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INTRODUCTION
Acute renal failure (ARF) is a common
complication in patients with decompen-
sated cirrhosis. The traditional diagnostic
criteria of renal failure in these patients
were proposed in 19961 and have been
refined in subsequent years.2 According to
these criteria, ARF is defined as an increase
in serum creatinine (sCr) of ≥50% from
baseline to a final value >1.5 mg/dL
(133 mmol/L). However, the threshold
value of 1.5 mg/dL (133 mmol/L) sCr to
define renal failure in patients with decom-
pensated cirrhosis has been challenged.3 4
In addition, the timeframe to distinguish
acute from chronic renal failure has not
been clearly identified, the only exception
being type 1 hepatorenal syndrome (HRS).
Meanwhile, new definitions for ARF, now
termed acute kidney injury (AKI), have
been proposed and validated in patients
without cirrhosis.5–7 Recently these new
criteria were also proposed and applied in
the diagnosis of AKI in patients with cir-
rhosis.3 8–15 Thus, in December 2012, the
International Club of Ascites (ICA) orga-
nised a consensus development meeting in
Venice, Italy, in order to reach a new defin-
ition of AKI in patients with cirrhosis. The
discussion among the experts continued
thereafter for 2 years, both online and
through several meetings, between those
experts who had different positions on
crucial points on the subject. This paper
reports the scientific evidence supporting
the final proposal of a new approach to the
diagnosis and treatment of this condition,
on which the experts agreed.
DIAGNOSTIC CRITERIA OF AKI AND
THEIR APPLICATION IN PATIENTS
WITH CIRRHOSIS
AKI is defined as an acute significant
reduction in the glomerular filtration rate
(GFR). sCr remains the most practical
biomarker of renal function in patients
with ARF (with or without cirrhosis).
However, sCr as a biomarker of renal
function has many limitations in clinical
practice since it is influenced by body-
weight, race, age, and gender. The use of
sCr in patients with cirrhosis is also
affected by: (1) decreased formation of
creatinine from creatine in muscles, sec-
ondary to muscle wasting;16 (2) increased
renal tubular secretion of creatinine;17 (3)
the increased volume of distribution in
cirrhosis that may dilute sCr; (4) interfer-
ence with assays for sCr by elevated biliru-
bin.18 As a consequence, measurement of
sCr in patients with cirrhosis overesti-
mates GFR or kidney function. Therefore,
the use of a fixed threshold of sCr at
1.5 mg/dL (133 mmol/L) to define AKI in
cirrhosis1 2 is problematic, because of two
crucial problems. The first is that an sCr
value of 1.5 mg/dL (133 mmol/L) often
signifies that GFR is markedly decreased
(to ∼30 mL/min);19 secondly, the fixed
threshold does not take into account the
dynamic changes in sCr that occur in the
preceding days or weeks, which are
needed to distinguish between acute and
chronic kidney injury. Since the use of a
single value of sCr is not sufficient to
diagnose AKI, a dynamic definition refer-
ring to an acute increase of sCr to ≥50%
from baseline to a final value ≥1.5 mg/dL
(133 mmol/L) has been used in several
clinical studies in patients with cirrhosis
(table 1). AKI, as defined by these criteria,
was a strong predictor of in-hospital mor-
tality in patients with cirrhosis.20–23
In recent years, diagnostic criteria have
been proposed for the diagnosis of ARF in
non-cirrhotic patients, now termed AKI.
In particular, two separate bodies devel-
oped and published two consensus defini-
tions of AKI: the Acute Dialysis Quality
Initiative group for the Risk, Injury,
Failure, Loss of Renal Function and
End-Stage Renal Disease (RIFLE) criteria;
and the Acute Kidney Injury Network
(AKIN) group for the AKIN criteria
(table 1).5 6 More recently, a panel of
experts has suggested combining part of
the AKIN criteria (increase of sCr of
0.3 mg/dL (26.5 mmol/L) within 48 h or
by ≥50% from baseline together with a
reduction in urine output to <0.5 mL/kg/h
for >6 h) with part of the RIFLE criteria
(increase of sCr ≥50% within 1 week or a
reduction in GFR by >25% together with
a reduction in urine output to <0.5 mL/
kg/h for >6 h), thus leading to the pro-
posal of the Kidney Disease Improving
Global Outcome (KDIGO) criteria7 (table 1).
However, the use of a reduction of urine
output in patients with cirrhosis and
ascites as a diagnostic criterion is a
problem, since these patients are fre-
quently oliguric with avid sodium reten-
tion and yet may maintain a relatively
normal GFR.24 Conversely, these patients
may have an increased urine output
because of diuretic treatment. Thus, urine
collection is often inaccurate in clinical
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practice and the use of kinetic changes in
sCr becomes the crux of the definition for
the diagnosis of AKI in cirrhosis.
The main differences between these
new criteria over the conventional criteria
in patients with cirrhosis are the follow-
ing: (1) an absolute increase in sCr is
considered; (2) the threshold of sCr
≥1.5 mg/dL (133 mmol/L) is abandoned;
and (3) a staging system of AKI, based on
a change in sCr over a slightly longer time
frame, arbitrarily set at 1 week to enable
assessment for progression of stage (modi-
fied from AKIN staging) as well as a
regression of stage (table 1). AKIN criteria
have been shown to be a good predictor
of mortality in large cohorts of hospita-
lised cirrhotic patients, including those in
intensive care units25 and the critically
ill.26 More recently, AKI as diagnosed
with AKIN criteria has been shown to be
associated with increased mortality in
patients with cirrhosis who were hospita-
lised in regular wards in an AKIN stage-
dependent fashion.8–13 15 Further, the
progression of AKI through stages (eg,
from stage 1 to 2 or stage 2 to 3) was
strongly correlated with an increased mor-
tality in these patients.8–10 Nevertheless, a
comparison of the prognostic accuracy of
the conventional criteria and the new cri-
teria in patients with cirrhosis was consid-
ered crucial for the development of a new
algorithm for the management of AKI
and was proposed by the ICA in 2011.3
However, the cut-off value of 1.5 mg/dL
(133 mmol/L) still has important reson-
ance with many clinicians. Two prospect-
ive studies have recently shown that a
cut-off value of sCr of 1.5 mg/dL (133
mmol/L) is useful to predict progression of
AKI and consequently the prognosis in
patients with cirrhosis.9 10 Thus, an sCr
≥1.5 mg/dL (133 mmol/L) was the only
predictive factor for progression of the
initial AKI stage (AKI stage at the first ful-
filment of AKIN criteria) to a higher AKI
stage during hospitalisation (peak AKI
stage). Thereafter, it was also shown that
the cut-off value of sCr ≥1.5 mg/dL
(133 mmol/L) was important when
patients with peak AKI stage 1 were con-
sidered. In fact, patients with AKI stage 1
could be divided into two groups: those
whose peak sCr did not exceed 1.5 mg/dL
(stage 1-A), whose short term mortality
might be similar to those without AKI and
in whom regression might occur more fre-
quently;9 10 and those whose peak sCr
exceeded 1.5 mg/dL (stage 1-B), whose
short term mortality was higher than those
without AKI.9 10 Patients with AKI stage 2
and 3 have the highest mortality.8–10
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be generalised to all hospitalised patients
with cirrhosis should be assessed in future
studies. In fact, as far as the impact of peak
AKI stage 1 on in-hospital mortality, it has
recently been observed that in patients
who developed AKI as a consequence of a
bacterial infection, those with stage 1 AKI
and a final sCr ≤1.5 mg/dL (133 mmol/L)
had a higher short term mortality com-
pared to those without AKI.13 27 In add-
ition, regarding regression of AKI stage, it
has recently been observed (in non-
hospitalised patients) that despite reso-
lution of most AKI episodes in patients
with advanced cirrhosis, a gradual and sig-
nificant increase in sCr and a gradual
reduction in mean arterial pressure were
observed during follow-up, associated
with a significant reduction in mid-term
survival compared with non-AKI
patients.11 Indeed, the main lesson learnt
from the application of AKIN criteria is
that even a small increase in sCr should be
identified as early as possible for potential
early interventions.
WHY DO WE NEED TO CHANGE THE
CONVENTIONAL DIAGNOSTIC
CRITERIA FOR AKI?
A recent editorial on the topic of AKI in
cirrhosis28 asked the question: “Should
we change current definition and diagnos-
tic criteria of renal failure in cirrhosis?”
Currently, studies on AKI in patients with
cirrhosis showed that AKI defined by an
absolute increase in sCr ≥0.3 mg/dL
(26.5 mmol/l) and/or ≥50% from baseline
is associated with a higher probability of
the patients being transferred to the inten-
sive care unit, a longer hospital stay, and
an increased in-hospital as well as 90-day
and mid-term mortality.8–15 On the basis
of this evidence, all the experts agreed
that it was time to change our current
definition of renal failure by introducing a
modified version of the KDIGO criteria
for the diagnosis of AKI in patients with
cirrhosis (table 2). In the new ICA criteria
for the diagnosis of AKI, the use of urine
output as one of the criteria has been
removed since it does not apply to
patients with cirrhosis (ie, many patients
are oliguric but have preserved kidney
function) and it has never been investi-
gated. Further, two other changes to the
KDIGO criteria were adopted, namely:
(1) a sCr within the last 3 months before
admission is considered a baseline value
for the diagnosis of AKI when a value
within the previous 7 days is not available;
and (2) the calculation of the baseline sCr
by the reverse application of the
Modification of Diet in Renal Disease
(MDRD) formula, using an arbitrarily
defined normal value of GFR of 75 mL/
min/1.73 m2, was not included. These
two points are specifically discussed in the
next section.
DEFINITION OF BASELINE SERUM
CREATININE FOR THE DIAGNOSIS OF AKI
The first step in applying the ICA-AKI cri-
teria is to define a baseline sCr. It has been
stated that a renal disease process that
results in a change in sCr over several
weeks cannot be defined as AKI, although
it may still represent an important clinical
entity.7 Nevertheless, as with any clinical
scenario, the timeframe for the definition
of AKI is somewhat arbitrary, and it is
mainly suitable for the diagnosis of AKI in
hospitalised patients using a sCr value on
or after admission as baseline (hospital-
acquired AKI). However, as in the general
population, many patients with cirrhosis
can develop AKI before admission to hos-
pital (community-acquired AKI). Indeed,
in previous studies where pre-admission
values of sCr were used as baseline, the
rate of AKI was higher than in those based
on sCr on admission as baseline (47% vs
26%).9 10 Thus, the diagnosis of
community-acquired AKI on admission is
related to two possible scenarios: (1) the
patient with an available sCr value before
admission; and (2) the patient without an
sCr value before admission. The use of
pre-admission values of sCr poses a great
dilemma: how far back can a baseline
value of sCr be retrieved and still be
expected to be ‘valid’ for the definition of
AKI? In the general population, it is rea-
sonable to assume that sCr will be stable
over several months or even years, so that
an sCr obtained 6 months or even 1 year
previously would reasonably reflect the
patient’s premorbid baseline.7 29 In
patients with cirrhosis, an application of a
more rigorous time frame for the defin-
ition of AKI seems even more important.
In fact, in these patients, impairment of
renal function may progress gradually as
they go from a compensated to a decom-
pensated state and then more rapidly as the
decompensated state worsens. In addition,
it should be considered that almost all
patients with cirrhosis and ascites receive
diuretics that can transiently impair renal
function and, thus, increase sCr.
Furthermore, it is important to empha-
sise the variability in sCr measurements
from laboratory to laboratory or even
within the same laboratory due to, for
example, fluctuations in serum bilirubin in
patients with cirrhosis.30 A sCr obtained
<7 days before admission would be the
ideal condition to use the ICA-AKI cri-
teria, but this timeframe seems unfeasible
in most cases. Thus, taking into account
the previous experiences, we conclude
that use of the last value of sCr within the
last 3 months before admission seems
Table 2 International Club of Ascites (ICA-AKI) new definitions for the diagnosis and management of AKI in patients with cirrhosis
Subject Definition
Baseline sCr A value of sCr obtained in the previous 3 months, when available, can be used as baseline sCr. In patients with more than one value within
the previous 3 months, the value closest to the admission time to the hospital should be used
In patients without a previous sCr value, the sCr on admission should be used as baseline
Definition of AKI Increase in sCr ≥0.3 mg/dL (≥26.5 mmol/L) within 48 h; ora percentage increase sCr ≥50% from baseline which is known, or presumed, to
have occurred within the prior 7 days
Staging of AKI Stage 1: increase in sCr ≥0.3 mg/dL (26.5 mmol/L) or an increase in sCr ≥1.5-fold to twofold from baseline
Stage 2: increase in sCr >two to threefold from baseline
Stage 3: increase of sCr >threefold from baseline or sCr ≥4.0 mg/dL (353.6 mmol/L) with an acute increase ≥0.3 mg/dL (26.5 mmol/L) or
initiation of renal replacement therapy
Progression of AKI Progression Regression
Progression of AKI to a higher stage and/or need for RRT Regression of AKI to a lower stage
Response to treatment No response Partial response Full response
No regression of AKI Regression of AKI stage with a reduction of sCr to ≥0.3 mg/dL
(26.5 mmol/L) above the baseline value
Return of sCr to a value within 0.3 mg/dL
(26.5 mmol/L) of the baseline value
AKI, acute kidney injury; RRT, renal replacement therapy; sCr, serum creatinine.
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more feasible.10 13 In this scenario, a
community-acquired AKI may be diag-
nosed in the case of an increase in sCr
≥50% from the last sCr value (table 2).
For patients without an available sCr
before hospitalisation, the use of an esti-
mated value of sCr as the baseline, calcu-
lated by the reverse application of the
MDRD formula using a predetermined
value of GFR (75 mL/min), has been sug-
gested for the general population of
patients.7 However, it is well known that
the MDRD formula is inaccurate in the
estimation of GFR in patients with cirrho-
sis, particularly in those with ascites.31 As
a result, its reverse application in these
patients may only add further biases.
Preliminary data from the Padua centre
suggest that a diagnosis of AKI based on
an computed value of sCr as baseline
identifies <25% of patients with a mea-
sured GFR <60 mL/min on admission
(Angeli P et al, unpublished observations).
However, among patients without an sCr
value before admission, one scenario
deserves specific mention, and that is the
case of the patient with an sCr ≥1.5 mg/
dL (133 mmol/L) at admission. The man-
agement of such a patient should be based
not only on a formal definition of AKI,
but also on clinical judgment. Therefore,
in a patient with impairment of renal
function and a clearly identifiable precipi-
tating event, it would be reasonable to
assume that the renal failure represents
AKI. Alternatively, the initial sCr may be
used as the baseline value, and if AKI
criteria are met subsequently then the
patient has AKI. This approach was
commonly used previously for the diagnosis
of type 1 HRS.32
A NEW ALGORITHM FOR THE
MANAGEMENT OF AKI IN PATIENTS
WITH CIRRHOSIS
According to the new ICA-AKI diagnostic
criteria for AKI, we propose a new algo-
rithm for the management of AKI in
patients with cirrhosis (figure 1). The algo-
rithm is based on the new staging of AKI.
We recommend that patients with cir-
rhosis and ascites with initial ICA-AKI
stage 1 should be managed as soon as pos-
sible with the following measures:
1. Review drug chart: review of all medi-
cations (including over-the-counter
(OTC) drugs), reduction or with-
drawal of diuretic therapy, withdrawal
of all potentially nephrotoxic drugs,
vasodilators or non-steroidal anti-
inflammatory drugs (NSAIDs)
2. Plasma volume expansion in patients
with clinically suspected hypovolaemia
(with crystalloids or albumin or blood
(in patients who had AKI as a result of
gastrointestinal bleeding) according to
clinical judgment)
3. Prompt recognition and early treat-
ment of bacterial infections when
diagnosed or strongly suspected.
Patients who respond with a return of
sCr to a value within 0.3 mg/dL
(26.5 mmol/L) of the baseline value
should be followed closely (assessment of
sCr every 2–4 days during the hospitalisa-
tion and checked as outpatients at least
every 2–4 weeks during the first 6 months
after the discharge) for early identification
of potential new episodes of AKI.11 In
those cases where there is progression of
the AKI stage, the patients should be
treated as patients who present with
ICA-AKI stage 2 and 3. This treatment
should include the withdrawal of diure-
tics, if this had not been previously imple-
mented, as well as the expansion of
plasma volume with intravenous albumin
at the dose of 1 g per kg bodyweight per
day for two consecutive days, in order to
treat pre-renal AKI and to allow differen-
tial diagnosis of AKI (box 1). The
maximal dose per day of albumin should
not exceed 100 g as previously suggested.2
Further management of patients who do
not respond to diuretic withdrawal and
plasma volume expansion will obviously
Figure 1 Proposed algorithm for the management of acute kidney injury (AKI) according to International Club of Ascites—AKI (ICA-AKI)
classification that combines Kidney Disease Improving Global Outcomes (KDIGO) criteria and conventional criteria in patients with cirrhosis and
ascites. Most of the experts had concerns about the use of vasoconstrictors in patients with AKI stage 1 and sCr <1.5 mg/dL. For the definition of
close follow-up, and/or case-by-case, see the text. *Treatment of spontaneous bacterial peritonitis should include albumin infusion according to
current guidelines. #Initial AKI stage is defined as AKI stage at the time of first fulfilment of the AKI criteria. §No global consensus was reached on
this point. HRS, hepatorenal syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; sCr, serum creatinine.
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depend on the final diagnosis of the AKI
type and, pragmatically, on the differential
diagnosis between an HRS-AKI, an intrin-
sic AKI, and post-renal-AKI (box 1).
Thus, another major contribution of this
new algorithm is to accelerate the differ-
ential diagnostic process among the differ-
ent types of AKI. However, it should be
highlighted that several steps of this algo-
rithm are not based on evidence but just
on experts’ opinion, and that it should be
validated in future prospective clinical
studies. In particular, in patients with AKI
stage 1 who do not respond but who do
not progress to a higher stage, no consen-
sus was obtained among the experts on
the specific treatment. All experts agreed
to treat these patients according to the
right side of the algorithm when the final
value of sCr is ≥1.5 mg/dL (133 mmol/L).
Some experts favour the treatment of
patients with AKI stage 1 and sCr
<1.5 mg/dL (133 mmol/L) in the same
way. However, most of the experts did
not agree on this because they had con-
cerns about the early use of vasoconstric-
tors (terlipressin or norepinephrine or
midodrine plus octreotide) in these
patients in case of HRS-AKI. Thus,
further clinical controlled studies are
needed to address this relevant issue. In
the meantime, decisions about the treat-
ment of these patients should be taken on
a case-by-case basis evaluating the aeti-
ology of AKI, the presence or absence of
precipitating factors, other organ failures,
or comorbid conditions that may contra-
indicate treatment.
WHY DO WE NEED TO CHANGE THE
DIAGNOSTIC CRITERIA OF HRS IN THE
SETTING OF AKI?
A major critical point in the management
of AKI in patients with decompensated
cirrhosis is whether the diagnostic criteria
of type 1 HRS should be revised in light
of the new definitions of AKI. The
current criteria include a time interval
(2 weeks) over which sCr must double to
a value >2.5 mg/dL for the diagnosis of
type 1 HRS.1 2 A revision of these criteria
is needed because the current definition
of type 1 HRS does not allow physicians
to initiate potentially effective treatment,
specifically vasoconstrictors and albumin,
until the sCr increases to ≥2.5 mg/dL.
Since it has been observed that in patients
with type 1 HRS, a higher sCr at the
beginning of treatment leads to a lower
probability of response to terlipressin and
albumin, the most investigated and effect-
ive treatment of type 1 HRS,33 34 it seems
prudent not to wait until the sCr increases
beyond 2.5 mg/dL before starting the
treatment. According to the new proposed
algorithm, when AKI is characterised by
an initial ICA-AKI stage 2 or 3 or by pro-
gression of the initial stage despite general
therapeutic measures, patients who
meet all other diagnostic criteria of HRS
provided by the previous definition2
should receive vasoconstrictors and
albumin, irrespective of the final value of
sCr. This makes it possible to remove a
barrier to the achievement of a pharmaco-
logical response that was linked to the
rigid sCr cut-off value of >2.5 mg/dL in
the definition of type 1 HRS. The poten-
tial advantage of the algorithm is that its
application may allow earlier treatment of
patients with type 1 HRS, leading to a
better outcome as compared with the
current approach. However, we lack
studies where vasoconstrictors were used
in the treatment of HRS with lower
values of sCr, and caution should be exer-
cised in the use of vasoconstrictors in
these patients pending further controlled
trials.
Nevertheless, all the experts agreed on
the removal of a fixed cut-off value of sCr
from the diagnostic criteria of HRS. This
is the only change that they wanted to
introduce in the current diagnostic criteria
for HRS. As a consequence, all the
remaining criteria are maintained (box 1).
However, these criteria do not rule out
the possibility of renal parenchymal
damage.35 Thus, all the experts agreed on
the potential role of new urinary biomar-
kers in the differential diagnosis of the
different types of AKI in patients with cir-
rhosis. Several urinary biomarkers of
tubular damage, such as neutrophil
gelatinase-associated lipocalin (NGAL),
kidney injury molecule-1 (KIM-1),
interleukin-18 (IL-18), and liver fatty
acid-binding protein (L-FABP), have been
discovered in recent years. Preliminary
experiences from Europe and the USA
showed that the use of NGAL36 and/or
the combination of urinary biomarkers
(NGAL, KIM-1, IL-18, L-FABP and albu-
minuria)37 may be useful in the differen-
tial diagnosis of AKI in patients with
cirrhosis. These findings need to be con-
firmed in future studies.
The removal of a fixed cut-off value of
sCr from the diagnostic criteria of HRS in
the setting of AKI has important implica-
tions in the management of these patients.
Thus, there is a need to change the defin-
ition of response to the pharmacologic
treatment of HRS. Full response will be
defined by return of sCr to a value within
0.3 mg/dL (26.5 mmol/L) of the baseline
value. Partial responses will be defined by
a regression of at least one AKI stage with
a fall in the sCr value to ≥0.3 mg/dL
(26.5 mmol/L) above the baseline value.
Nevertheless, we should recognise that
preliminary data suggest that even a
partial decrease of sCr from baseline may
be associated with improved short term
survival, irrespective of whether or not
the patient achieves HRS reversal (sCr
<1.5 mg/dL).38 These data suggest that
the degree of improvement in sCr may be
more relevant than achieving a finite level
of renal function.
Box 1 Diagnostic criteria of hepatorenal syndrome (HRS) type of acute kidney
injury (AKI) in patients with cirrhosis
HRS-AKI
▸ Diagnosis of cirrhosis and ascites
▸ Diagnosis of AKI according to ICA-AKI criteria
▸ No response after 2 consecutive days of diuretic withdrawal and plasma volume
expansion with albumin 1 g/kg bodyweight
▸ Absence of shock
▸ No current or recent use of nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated
contrast media, etc)
▸ No macroscopic signs of structural kidney injury*, defined as:
– absence of proteinuria (>500 mg/day)
– absence of microhaematuria (>50 RBCs per high power field)
– normal findings on renal ultrasonography
*Patients who fulfil these criteria may still have structural damage such as tubular
damage. Urine biomarkers will become an important element in making a more accurate
differential diagnosis between HRS and acute tubular necrosis.
ICA, International Club of Ascites; NSAIDs, non-steroidal anti-inflammatory drugs; RBCs,
red blood cells.
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CONCLUSIONS AND FUTURE
PERSPECTIVES
Based on the most recent studies on AKI
in patients with cirrhosis and ascites, a
new algorithm for the management of
AKI in these patients is proposed for clin-
ical practice and for future research. The
main innovative aspects of this new algo-
rithm are the following:
▸ The adoption of the main point
derived from the application of the
KDIGO criteria in the definition of
AKI in patients with cirrhosis, namely,
use of dynamic changes of sCr
▸ A more structured diagnostic process,
in order to allow a rational application
of the therapeutic resources, avoiding
potentially undesirable consequences
of overtreatment of AKI as a result of
indiscriminant use of KDIGO criteria
▸ The definitive removal of any cut-off
value of sCr from the criteria for diag-
nosis of HRS in the setting of AKI, but
maintaining the remaining previous
criteria (box 1).
Several issues remain to be addressed:
(1) the impact of the management of AKI
according to the new algorithm on the
outcome of these patients should be
tested in future prospective studies; and
(2) the role of the new biomarkers of
renal tubular damage in predicting the
progression and prognosis of AKI, and in
the differential diagnosis of the different
types of AKI.36 37
In summary, the results of the latest
consensus conference of the ICA intro-
duces a new dynamic definition of AKI in
patients with cirrhosis, on which a new
treatment algorithm is based, representing
a substantial change from the traditional
criteria used until now in the definition of
AKI and type 1 HRS.
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